Cargando…
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
BACKGROUND: There is still a substantial unmet need for less invasive and lower-cost blood-based biomarkers to detect brain Alzheimer’s disease (AD) pathology. This study is aimed to determine whether quantification of plasma tau phosphorylated at threonine 181 (p-tau181) is informative in the diagn...
Autores principales: | Tatebe, Harutsugu, Kasai, Takashi, Ohmichi, Takuma, Kishi, Yusuke, Kakeya, Tomoshi, Waragai, Masaaki, Kondo, Masaki, Allsop, David, Tokuda, Takahiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582385/ https://www.ncbi.nlm.nih.gov/pubmed/28866979 http://dx.doi.org/10.1186/s13024-017-0206-8 |
Ejemplares similares
-
Increased levels of plasma total tau in adult Down syndrome
por: Kasai, Takashi, et al.
Publicado: (2017) -
Cerebral spinal fluid biomarker profiles in CNS infection associated with HSV and VZV mimic patterns in Alzheimer’s disease
por: Shinomoto, Makiko, et al.
Publicado: (2021) -
Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients
por: Shinomoto, Makiko, et al.
Publicado: (2019) -
Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy
por: Kasai, Takashi, et al.
Publicado: (2016) -
Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics
por: Kojima, Yuta, et al.
Publicado: (2021)